Who owns Eikon Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of EIKN from SEC Form 13F filings across 77 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 77 institutions disclosed 26.5M shares of Eikon Therapeutics, Inc. worth $344.1M — about 48.9% of shares outstanding; the largest disclosed holder is FMR LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
77
13F holders
$344.1M
value, 2026 filers
48.9%
of shares outstanding (26.5M sh)
37
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of EIKN's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | 5.0M | $65.2M | 0.0% | 9.2% | +30.2% |
| 2 | BlackRock, Inc. | 4.3M | $55.9M | 0.0% | 7.9% | +29.0% |
| 3 | Foresite Capital Management IV, LLC | 1.9M | $25.4M | 8.7% | 3.6% | 0.0% |
| 4 | Merck & Co., Inc. | 1.7M | $21.7M | 4.1% | 3.1% | 0.0% |
| 5 | T. Rowe Price Investment Management, Inc. | 1.6M | $20.8M | 0.0% | 2.9% | +30.5% |
| 6 | Foresite Capital Management V, LLC | 1.3M | $17.2M | 4.8% | 2.4% | 0.0% |
| 7 | Capital World Investors | 1.2M | $15.3M | 0.0% | 2.2% | +2.8% |
| 8 | PRICE T ROWE ASSOCIATES INC /MD/ | 1.0M | $13.1M | 0.0% | 1.9% | +3.0% |
| 9 | VANGUARD CAPITAL MANAGEMENT LLC | 922,707 | $12.0M | 0.0% | 1.7% | -4.8% |
| 10 | EcoR1 Capital, LLC | 732,606 | $9.6M | 0.5% | 1.4% | 0.0% |
| 11 | ALLIANCEBERNSTEIN L.P. | 641,888 | $6.8M | 0.0% | 1.2% | -37.2% |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 556,955 | $7.3M | 0.0% | 1% | +103.3% |
| 13 | BAKER BROS. ADVISORS LP | 555,555 | $7.2M | 0.0% | 1% | 0.0% |
| 14 | SOROS CAPITAL MANAGEMENT LLC | 484,672 | $6.3M | 1.1% | 0.9% | 0.0% |
| 15 | StepStone Group LP | 395,340 | $5.2M | 0.2% | 0.7% | 0.0% |
| 16 | CANADA PENSION PLAN INVESTMENT BOARD | 379,024 | $4.9M | 0.0% | 0.7% | 0.0% |
| 17 | STATE STREET CORP | 354,093 | $4.6M | 0.0% | 0.7% | +781.9% |
| 18 | FRANKLIN RESOURCES INC | 350,000 | $4.6M | 0.0% | 0.6% | 0.0% |
| 19 | General Catalyst Group Management, LLC | 305,233 | $4.0M | 2.1% | 0.6% | 0.0% |
| 20 | UBS Group AG | 263,932 | $3.4M | 0.0% | 0.5% | +165.5% |
| 21 | Parkman Healthcare Partners LLCNEW | 256,053 | $3.3M | 0.3% | 0.5% | new |
| 22 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 182,105 | $2.4M | 0.0% | 0.3% | +38.9% |
| 23 | Schonfeld Strategic Advisors LLCNEW | 179,775 | $2.3M | 0.0% | 0.3% | new |
| 24 | NORTHERN TRUST CORP | 175,927 | $2.3M | 0.0% | 0.3% | +286.4% |
| 25 | Ensign Peak Advisors, Inc | 170,490 | $2.2M | 0.0% | 0.3% | -14.8% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.